

# Sotrovimab Access Form (Hospitalised Patients)

Write in CAPITAL LETTERS or use addressograph

Surname: \_\_\_\_\_

First names: \_\_\_\_\_

Health and Care No: \_\_\_\_\_

DOB: \_\_\_\_\_

Ward/Department: \_\_\_\_\_

Weight: \_\_\_\_\_ eGFR: \_\_\_\_\_

**Allergies / Medicine sensitivities**  
 This section must be completed before prescribing and administration except in exceptional circumstances

Date of Reaction	Medicine/allergen	Type of reaction (eg. rash)	Signature/designation/date

OR

No known allergies (Please tick)

Signature / Designation: \_\_\_\_\_ Date: \_\_\_\_\_

Inclusion Criteria (ALL MUST APPLY)	Indicate Yes or No
SARS-CoV-2 infection is confirmed by either PCR testing <b>or</b> lateral flow test.	
Symptomatic with COVID-19 and showing no signs of clinical recovery.	
Patient has an increased risk for progression to severe COVID-19 ( <a href="#">as defined in section 5 of NICE's technology appraisal guidance</a> ).	<b>Please state risk group</b>
Treatment with nirmatrelvir plus ritonavir is contraindicated or unsuitable.	
Treatment commenced within <b>FIVE</b> days of symptom onset.	
Off-label treatment may be commenced on days 6 or 7 post symptom onset if clinically appropriate (see below)	
Exclusion Criteria (Patients are not eligible if they meet any of the following)	Indicate Yes or No
New supplemental oxygen requirement specifically for the management of COVID-19 symptoms.	
Child aged less than 12 years .	
Weight less than 40kg.	
Known hypersensitivity to sotrovimab or to any of the excipients of Xevudy® (histidine, histidine monohydrochloride, sucrose, polysorbate 80, methionine, water for injection).	
<p><b>Medications have been reviewed</b> (please tick box and sign) <input type="checkbox"/> Signature: _____</p> <p><b>Renal impairment:</b> no dose adjustment is required in patients with renal impairment. Limited data in severe renal impairment – clinical decision</p> <p><b>Hepatic impairment:</b> no dose adjustment is required in patients with hepatic impairment. No data in severe hepatic impairment – clinical decision</p> <p><b>Pregnancy and breastfeeding:</b> No data for use in pregnant women or breastfeeding. The SmPC for Sotrovimab states that it may be used during pregnancy where the expected benefit to the mother justifies the risk to the foetus. Sotrovimab can be used with caution and infant monitoring during breastfeeding. Monitor for adequate feeding and hypersensitivity reactions.</p> <p><b>Weight:</b> No data for use in adults weighing &lt;40kg – clinical decision</p> <p><b>Off-label treatment</b> may be commenced on days 6 or 7 post symptom onset if clinically appropriate. If prescribing on day 6-7 post symptom onset patients should be advised that this is “off-label”. This is not referenced in COVID-19 rapid guideline: Managing COVID-19 published 23 March 2021 updated 13/03/2024 Accessed 24/04/2024 but is referenced in the Interim Clinical Commissioning Policy: Treatment for non-hospitalised patients with COVID-19. Publication date:28th November 2022.</p>	

SHSCT Pharmacy Department Version 4.0 (Updated 09/05/2024 Review 09/05/2025)

**References**

Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 Published: 29 March 2023 Last updated: 13 March 2024 available at [Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 \(nice.org.uk\)](#)

COVID-19 rapid guideline: managing COVID-19 Published: 23 March 2021 Last updated: 08 May 2024 available at [Overview | COVID-19 rapid guideline: managing COVID-19 | Guidance | NICE](#)

Interim Clinical Commissioning Policy: Treatment for non-hospitalised patients with COVID-19. Publication date:28th November 2022

Sotrovimab (Xevudy®) 500mg concentrate for solution for infusion – Summary of Product Characteristics (SmPC) – (emc) <https://www.medicines.org.uk/emc/product/13097>

SPS: Managing COVID-19 and breastfeeding. Published 06/10/2023. Accessed 09/05/2024. [Managing COVID-19 and breastfeeding – SPS - Specialist Pharmacy Service – The first stop for professional medicines advice](#)

## Sotrovimab Access Form (Hospitalised Patients)

DRUG	DOSE	Fluid	Time	DAY	Route	Additional Info
<b>Sotrovimab (Xevudy®)</b>	<b>500mg</b>	<b>50ml 0.9% sodium chloride</b>	<b>30 minutes</b>	<b>1</b>	<b>IV</b>	<b>Administer with a 0.2 micron in-line filter</b>

Prescriber's Signature: _____ Prescriber's Name: _____ Grade: _____ GMC _____ Contact No: _____	Date: _____
--	-------------

### Pharmacy Section:

**Scanned copies to be sent to pharmacy, after clinical check on ward. If not clinically checked on ward, original must be sent to Pharmacy Department.**

CC	LAB	DISP	FC	DATE

### Administration information:

- Sotrovimab is a monoclonal antibody. Reduce direct handling to a minimum and wear appropriate PPE. [Injectable Medicines Guide - Display - Sotrovimab - Intravenous - Version 3 - IVGuideDisplayMain.asp \(medusaimg.nhs.uk\)](https://www.nhs.uk/medicines/sotrovimab/)
- A fluid balance chart must be completed to allow administration to occur
- Sotrovimab (Xevudy®) should not be infused concomitantly in the same IV line with other medicines
- Sotrovimab must be diluted prior to administration.
- Once diluted, attach an infusion set to the infusion bag using standard bore tubing. The intravenous dosing solution is recommended to be administered with a 0.2 µm in-line filter.
- Treatment must not be administered as an intravenous push or bolus.
- SPS recommends that 8ml Sotrovimab (Xevudy®) solution is added to the bag of sodium chloride 0.9% without removing an aliquot from the bag. [Handling and preparation of sotrovimab – SPS - Specialist Pharmacy Service – The first stop for professional medicines advice](#)
- All patients must be observed post infusion for acute infusion-related reactions/hypersensitivity reactions as per local policy – refer to the Summary of Product Characteristics (SmPC) and Interim Clinical Commissioning Policy for further information
- Report any suspected adverse reactions via [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard)

SHSCT Pharmacy Department Version 4.0 (Updated 09/05/2024 Review 09/05/2025)

#### References

Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 Published: 29 March 2023 Last updated: 13 March 2024 available at [Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 \(nice.org.uk\)](https://www.nhs.uk/medicines/nirmatrelvir-plus-ritonavir-sotrovimab-and-tocilizumab-for-treating-covid-19/)

COVID-19 rapid guideline: managing COVID-19 Published: 23 March 2021 Last updated: 08 May 2024 available at [Overview | COVID-19 rapid guideline: managing COVID-19 | Guidance | NICE](https://www.nice.org.uk/guidance/NG195)

Interim Clinical Commissioning Policy: Treatment for non-hospitalised patients with COVID-19. Publication date: 28th November 2022

Sotrovimab (Xevudy®) 500mg concentrate for solution for infusion – Summary of Product Characteristics (SmPC) – (emc) <https://www.medicines.org.uk/emc/product/13097>

SPS: Managing COVID-19 and breastfeeding. Published 06/10/2023. Accessed 09/05/2024. [Managing COVID-19 and breastfeeding – SPS - Specialist Pharmacy Service – The first stop for professional medicines advice](#)